Copyright © 2021 Pharmascimed. All Rights Reserved.
Aimovig
- Home
- Aimovig
NICE rejects Novartis’ migraine drug for routine use
- January 9, 2019
- 0
The National Institute for Health Care and Excellent (NICE) has rejected Novartis' migraine drug Aimovig (erenumab) as preventative treatment for migraine in draft guidelines. The news comes after Aimovig was...
Read moreTrending
Recent Posts
The coming age of biosimilars
- February 26, 2019
- 0
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
AbbVie and Voyager Therapeutics in Parkinson’s Pact
- February 22, 2019
- 0